| Prospects for a MERS-CoV spike vaccine |
36 |
| The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations |
25 |
| Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials |
22 |
| Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis |
21 |
| Vaccine candidates against leishmania under current research |
19 |
| Decreased performance of live attenuated, oral rotavirus vaccines in low-income settings: causes and contributing factors |
18 |
| Underlying factors impacting vaccine hesitancy in high income countries: a review of qualitative studies |
18 |
| Immunological basis for enhanced immunity of nanoparticle vaccines |
16 |
| Vaccination of healthcare workers: is mandatory vaccination needed? |
16 |
| Glycoconjugate vaccines: current approaches towards faster vaccine design |
16 |
| Foot and mouth disease vaccine strain selection: current approaches and future perspectives |
15 |
| Current challenges for cancer vaccine adjuvant development |
15 |
| From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine |
14 |
| Progress on norovirus vaccine research: public health considerations and future directions |
14 |
| Virus-like particle vaccines: immunology and formulation for clinical translation |
14 |
| A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection |
13 |
| Escherichia coli and Staphylococcus aureus: leading bacterial pathogens of healthcare associated infections and bacteremia in older-age populations |
13 |
| A review of 65 years of human adenovirus seroprevalence |
13 |
| Malaria vaccines in the eradication era: current status and future perspectives |
12 |
| Basics of CD8 T-cell immune responses after influenza infection and vaccination with inactivated or live attenuated influenza vaccine |
12 |
| Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention |
12 |
| A decade of experience with rotavirus vaccination in the United States - vaccine uptake, effectiveness, and impact |
11 |
| Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV) |
11 |
| Update on non-typeable Haemophilus influenzae-mediated disease and vaccine development |
11 |
| Enhancing uptake of influenza maternal vaccine |
11 |
| Developing a vaccine for type 1 diabetes by targeting coxsackievirus B |
10 |
| Flagellin as a vaccine adjuvant |
10 |
| Eradication of human papillomavirus and elimination of HPV-related diseases - scientific basis for global public health policies |
9 |
| Do varicella vaccination programs change the epidemiology of herpes zoster? A comprehensive review, with focus on the United States |
9 |
| Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine |
9 |
| Current perspectives in assessing humoral immunity after measles vaccination |
9 |
| The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients |
9 |
| Meningococcal B vaccine (4CMenB): the journey from research to real world experience |
8 |
| Influenza vaccine failure: failure to protect or failure to understand? |
8 |
| Extracellular vesicles from parasitic helminths and their potential utility as vaccines |
8 |
| Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy |
8 |
| Estimated impact of rotavirus vaccine on hospitalizations and deaths from rotavirus diarrhea among children < 5 in Asia |
8 |
| Effectiveness of the trivalent MF59 adjuvated influenza vaccine in preventing hospitalization due to influenza B and A(H1N1)pdm09 viruses in the elderly in Italy, 2017-2018 season |
7 |
| Systematic review of the clinical development of group B streptococcus serotype-specific capsular polysaccharide-based vaccines |
7 |
| Universal influenza vaccines: from viruses to nanoparticles |
7 |
| Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution |
7 |
| Single-cycle adenovirus vectors in the current vaccine landscape |
7 |
| Adjuvanted versus nonadjuvanted influenza vaccines and risk of hospitalizations for pneumonia and cerebro/cardiovascular events in the elderly |
7 |
| Recent advancements toward therapeutic vaccines against Alzheimer's disease |
7 |
| Passive and active antibody studies in primates to inform HIV vaccines |
7 |
| Vaccines against human respiratory syncytial virus in clinical trials, where are we now? |
6 |
| The influence of BCG on vaccine responses - a systematic review |
6 |
| Challenges in estimating influenza vaccine effectiveness |
6 |
| Aiming for protective T-cell responses: a focus on the first generation conserved-region HIVconsv vaccines in preventive and therapeutic clinical trials |
6 |
| Immunogenicity of high-dose trivalent inactivated influenza vaccine: a systematic review and meta-analysis |
6 |
